A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Nobuhiko, Kasahara, Senji, Kitagawa, Junichi, Nakamura, Hiroshi, Sawada, Michio, Fukuno, Kenji, Shibata, Yuhei, Kaneda, Yuto, Hara, Takeshi, Kanemura, Nobuhiro, Tsurumi, Hisashi, Shimizu, Masahito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876747/
https://www.ncbi.nlm.nih.gov/pubmed/35216626
http://dx.doi.org/10.1186/s40164-022-00264-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876747/
https://www.ncbi.nlm.nih.gov/pubmed/35216626
http://dx.doi.org/10.1186/s40164-022-00264-3

Ejemplares similares